Research Papers:
Effect of PKC inhibitor on experimental autoimmune myocarditis in Lewis rats
Metrics: PDF 1668 views | HTML 3111 views | ?
Abstract
Chunlian Zhong1, Yang Wu1,2, He Chang1,2, Chunxiao Liu1,2, Li Zhou1, Jun Zou1 and Zhi Qi1
1Department of Basic Medical Sciences, Medical College of Xiamen University, Xiang’an Nan Lu, Xiamen, China
2Xiamen Cardiovascular Hospital, Medical College of Xiamen University, Xiamen, China
Correspondence to:
Jun Zou, email: [email protected]
Zhi Qi, email: [email protected]
Keywords: myocarditis, PKC signaling, PKC inhibitor, apoptosis, inflammation
Abbreviations: EAM-experimental autoimmune myocarditis, ANP-atrial natriuretic peptide, BNP-brain natriuretic peptide
Received: January 02, 2017 Accepted: March 31, 2017 Published: April 10, 2017
ABSTRACT
Myocarditis is a major cause of sudden, unexpected death in young people. However, it is still one of the most challenging diseases to treat in cardiology. In the present study, we showed that both expression level and activity of PKC-α were up-regulated in the rat heart of experimental autoimmune myocarditis (EAM). Intraperitoneal administration of PKC inhibitor (Ro-32-0432) at the end of the most severe inflammation period of EAM still significantly reduced the EAM induced expression of failure biomarkers. Furthermore, Ro-32-0432 reduced the ratio of Bax/Bcl-2 and suppressed the expression of cleaved caspase-3, both of which were increased in the heart of the EAM rats, suggesting an anti-apoptotic role of Ro-32-0432. Besides, Ro-32-0432 suppressed EAM-induced cardiac fibrosis and release of pro-inflammatory cytokines IL-1β and IL-17. These results suggest that inhibition of PKC may serve as a potential therapeutic strategy for the treatment of myocarditis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17018